ACC 2022: A Step Towards Prime Time for a Breakthrough in Lipid Management

Anum Saeed, MD


April 07, 2022

Amid the flurry of activity at the American College of Cardiology 2022 Scientific Session, Anum Saeed, MD, reports on the positive results of the APOLLO trial, which support the efficacy of the short interfering RNA agent SLN360 in reducing lipoprotein (a) levels. This is a watershed moment in the treatment of this lipid disorder, which currently has no direct, approved therapeutic agent.

Dr Saeed cautions that the phase 2 and 3 trials must still occur before SLN360 is ready for "prime time"; however, early results offer promise to those afflicted by this disorder.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.